Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/13221
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRowland, A Jen
dc.contributor.authorPietersz, Geoffrey Aen
dc.date.accessioned2015-05-16T03:02:05Z
dc.date.available2015-05-16T03:02:05Z
dc.date.issued1994-08-01en
dc.identifier.citationCancer Immunology, Immunotherapy : Cii; 39(2): 135-9en
dc.identifier.govdoc8044832en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/13221en
dc.description.abstractAlthough aminopterin(AMN)-antibody drug conjugates have been demonstrated to have a greatly increased antitumor efficacy compared to the free drug, their use is limited by an increase in systemic toxicity manifested by weight loss and bone marrow suppression. Using a murine thymoma model (E3) in inbred mice, the toxicity of a sublethal dose of free AMN could be prevented by the administration of leucovorin 24 h following drug treatment, whilst maintaining the antitumour effect of the drug. The same rescue protocol completely abrogated the antitumour efficacy of AMN-antibody, although toxicity was also diminished. However, the later administration of leucovorin 48-72 h following a sublethal dose of AMN-antibody conjugates resulted in a maintenance of the anti-tumour efficacy of the immunoconjugates and a reduction in toxicity, with a mean percentage change in mouse weight not significantly different from that of the controls. These studies demonstrate that reversal of toxicity caused by AMN-antibody conjugates can be achieved by leucovorin while maintaining a powerful antitumour effect provided that the dose of leucovorin is administered 48-72 h after the conjugate.en
dc.language.isoenen
dc.subject.otherAminopterin.toxicityen
dc.subject.otherAnimalsen
dc.subject.otherAntibodies, Monoclonalen
dc.subject.otherAntigens, Ly.immunologyen
dc.subject.otherImmunotoxins.analysis.therapeutic useen
dc.subject.otherLeucovorin.therapeutic useen
dc.subject.otherMiceen
dc.subject.otherMice, Inbred BALB Cen
dc.subject.otherMice, Inbred C57BLen
dc.subject.otherNeoplasm Transplantationen
dc.subject.otherThymoma.drug therapyen
dc.subject.otherThymus Neoplasms.drug therapyen
dc.titleReduction in the toxicity of aminopterin--monoclonal-antibody conjugates by leucovorin.en
dc.typeJournal Articleen
dc.identifier.journaltitleCancer immunology, immunotherapy : CIIen
dc.identifier.affiliationAustin Research Institute, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages135-9en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/8044832en
dc.type.austinJournal Articleen
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

8
checked on Feb 7, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.